Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic Dermatitis

The results of this cohort study suggest that dupilumab demonstrates long-term effectiveness and safety in pediatric AD in a clinical setting. Younger children show higher NRS scores for pruritus and greater QoL impairment and discontinue treatment more often due to administration problems, highlighting age-specific challenges.

Corresponding Author: Marlies de Graaf, MD, PhD, Heidelberglaan 100, PO box 85500, 3584 CX Utrecht, The Netherlands (m.degraaf-10@umcutrecht.nl).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.